GPCM
GANX icon

Granite Point Capital Management’s Gain Therapeutics GANX Stock Holding History

Granite Point Capital Management’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-155,709
Closed -$1.56M – 153
2021
Q2 		$1.56M Sell
155,709
-69,291
-31% -$782K 0.06% 97
2021
Q1 		$3.36M Buy
+225,000
New +$2.95M 0.13% 62

Other funds holding GANX

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
IAP
Indie Asset Partners Carmel, Indiana $87.8M AUM 27.76% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $2.66B AUM 26.89% 1-Year Est. Return

Granite Point Capital Management's GANX Position: Q3 2021 in Review

Granite Point Capital Management sold out of Gain Therapeutics (GANX) in Q3 2021, closing a stake of 155,709 shares — an estimated $1.56M sold.

Granite Point Capital Management first reported a position in GANX in Q1 2021 and held it in 2 quarters. The position peaked at $3.36M in Q1 2021. 14 funds tracked by Wall St. Rank hold GANX as of Q3 2021.

  • Granite Point Capital Management reported no remaining Gain Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Granite Point Capital Management sold 155,709 Gain Therapeutics shares in Q3 2021, an estimated $1.56M.
  • Granite Point Capital Management first reported a position in Gain Therapeutics in Q1 2021 and held it in 2 quarters.
  • Granite Point Capital Management's Gain Therapeutics position peaked at $3.36M in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2021.

Based on Granite Point Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.